Orlando Health

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

EvidenceCare, LLC is a company that designs and develops decision support tools and web applications for clinicians, aimed at enhancing the delivery of medical care and treatment procedures. Established in 2014 and based in Brentwood, Tennessee, EvidenceCare offers a clinical decision support system (CDSS) that integrates seamlessly into a clinician's electronic health record (EHR) workflow. This platform provides customized, interactive guidance to healthcare providers, promoting evidence-based care with measurable outcomes. Key features of EvidenceCare include Pathway Builder, which allows health systems to create tailored care pathways; Admission Criteria, designed to minimize denial rates and maximize reimbursements for hospitals; and Imaging Criteria, which ensures compliance with appropriate use criteria for advanced imaging services. By leveraging advanced CDSS technology, EvidenceCare helps healthcare organizations improve quality and safety, reduce liability, enhance operational efficiency, and capture additional revenue while adhering to government compliance requirements.

Francis Medical is a medical technology company focused on developing innovative therapeutic solutions for prostate, kidney, and bladder cancers. The company is advancing a device that utilizes water vapor technology to treat prostate cancer, which is the second most prevalent cancer among men in the United States. This novel approach employs the thermal energy stored in sterile water vapor to ablate cancerous tissue through a straightforward transurethral procedure. By targeting cancerous cells while safeguarding surrounding healthy structures, Francis Medical aims to minimize the severe side effects often associated with traditional cancer treatments, thereby improving patient outcomes.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

Brookwood Baptist Health provides patients with a primary care network in the state. They customize treatments and services based on the needs of each patient, backed by a large network of resources, expertise, innovation, and locations. They strive to serve and develop meaningful relationships with the people in their communities to earn their trust.

Endogenex is a medical technology company founded in 2017, focused on developing innovative solutions for patients with type 2 diabetes. The company has created an endoscopic procedure that employs pulsed electric fields to regenerate the duodenal mucosa, aiming to enhance glycemic control in individuals suffering from this condition. By providing a novel therapy, Endogenex seeks to empower patients to better manage their blood glucose levels and improve their overall health outcomes.

Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2015. The company specializes in developing biologics and small molecules aimed at enhancing patient care. Arrivo BioVentures focuses on creating reformulated biopharmaceutical drugs and new chemical entities, employing its expertise in drug development to identify effective regulatory strategies. By coordinating closely with regulatory bodies such as the FDA, the company seeks to streamline the approval process and efficiently implement clinical programs for its products. This approach minimizes potential challenges and accelerates the development timeline, ultimately contributing to improved patient outcomes.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Developer of a portable, point-of-care hemodynamic measurement platform that uses proprietary sensor technology and machine learning to guide critical patient management decisions in heart failure, sepsis, pulmonary hypertension, and other critical diseases. The Sensydia Cardiac Performance System™ (CPS) is entirely non-invasive, trained to gold standard, and can be deployed in minutes in the hospital, clinic, office or at home. By making hemodynamic insights as accessible as routine blood pressure readings, CPS will enable early disease detection and improve disease management through accurate, easy-to-use, non-invasive monitoring.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Vergent Bioscience, Inc. is a company focused on improving cancer surgery outcomes through the development of molecularly-targeted imaging probes. Founded in 2013 and based in Minneapolis, Minnesota, Vergent manufactures a tumor-targeted fluorescent probe, known as VGT-309, which binds to enzymes overexpressed in various cancerous tissues. Upon injection prior to surgery, this probe activates a bright fluorescing dye that illuminates cancerous cells, allowing surgeons to differentiate between malignant and normal tissue with enhanced clarity. By providing a clear visual guide during surgical procedures, Vergent's technology aims to facilitate the complete removal of tumors and reduce the likelihood of residual cancer, thereby addressing a critical need in the surgical oncology field. The company's innovative approach is applicable to multiple cancer types, including lung, breast, ovarian, colorectal, and brain cancers, and is designed to support advanced visualization in various surgical techniques, including open, laparoscopic, and robotic surgeries.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Florida Heart & Vascular Center offers services that are far-reaching in breadth and scope and a team of consultative.

BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution. BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease. BioStable was founded in

Phynd Technologies Inc. is a healthcare technology company based in Dallas, Texas, founded in 2012. It offers a Software-as-a-Service data management platform designed to simplify the management of healthcare provider data for organizations across the United States. The platform, known as Unified Provider Management (UPM), serves as a central hub for managing critical provider information, including billing addresses, communication preferences, licensing details, and exclusionary lists. Additionally, the platform includes tools for provider enrollment, management, outreach, and search, ensuring that healthcare systems can efficiently maintain and utilize provider data across electronic health records, marketing, and claims systems. Phynd Technologies has gained traction in the healthcare industry, with over 350 hospitals and more than 20,000 locations utilizing its solutions to enhance financial outcomes and clinical results while minimizing compliance risks. The company also offers verification services to further support its clients.

Gauss Surgical, Inc. specializes in real-time blood monitoring solutions that enhance clinical decision-making in the healthcare sector. The company has developed a vision-based platform that provides accurate estimations of blood loss, facilitating timely transfusion decisions and improving patient outcomes. Its flagship product, Triton, is utilized in obstetrics to aid in the early detection of postpartum hemorrhage and offers objective metrics for assessing blood loss. Additionally, Gauss Surgical offers Triton OR, designed for operating rooms to measure blood loss from surgical sponges and suction canisters, and Triton L&D, which focuses on vaginal delivery and postpartum care. Founded in 2011, Gauss Surgical operates from its headquarters in Menlo Park, California.

MRI